FTC demands AbbVie divests Crohn’s treatment in Allergan buyout

The US Federal Trade Commission has approved a final order regarding charges that biopharmaceutical company AbbVie’s $63 billion acquisition of Allergan would violate US federal antitrust law.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

FTC urges Congress to step in over AbbVie antitrust claim

3 August 2021 The US Federal Trade Commission has dropped its remaining claim in a lawsuit against AbbVie and Besins Healthcare, after the US Supreme Court declined to rule that consumers had a right to be compensated by the companies.

Big Pharma

Judge rejects Allergan challenge to FCA suit

15 December 2020 A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.

Big Pharma

Fed Circuit remands Allergan inventorship dispute

11 November 2020 The US Court of Appeals for the Federal Circuit concluded that a New York judge had rushed to grant summary judgment in an inventorship dispute between Ferring and Allergan.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

FTC demands AbbVie divests Crohn’s treatment in Allergan buyout

More on this story

Editor's picks

Editor's picks

More features